safe
potent
broadspectrum
antivir
urgent
need
combat
emerg
respiratori
virus
light
broad
antivir
activ
test
antivir
activ
peptid
deriv
mous
found
short
peptid
exhibit
potent
broadspectrum
antivir
effect
multipl
respiratori
virus
vitro
vivo
includ
influenza
viru
sarscov
merscov
antivir
activ
attribut
highaffin
bind
viral
glycoprotein
well
abund
basic
amino
acid
composit
bind
viral
particl
viral
surfac
glycoprotein
enter
cell
togeth
virus
via
endocytosi
prevent
endosom
acidif
block
membran
fusion
subsequ
viral
rna
releas
studi
pave
avenu
develop
new
prophylact
therapeut
agent
broadspectrum
antivir
activ
rang
respiratori
virus
vitro
vivo
addit
seri
experi
unveil
uniqu
antivir
mechan
pandem
epidem
respiratori
virus
import
sourc
mortal
morbid
among
human
popul
recurr
outbreak
highli
pathogen
influenza
viru
infect
poultri
sporad
transmiss
human
sinc
result
high
mortal
rate
intermitt
outbreak
influenza
sinc
kill
inflict
individu
addit
emerg
sever
acut
respiratori
syndrom
sar
middleeast
respiratori
syndrom
mer
result
mortal
rate
respect
rais
concern
potenti
outbreak
fatal
virus
previous
unknown
human
commun
view
limit
efficaci
current
vaccin
antivir
drug
respiratori
viral
infect
emerg
new
respiratori
virus
new
agent
broadspectrum
antivir
effect
desper
need
prevent
treatment
respiratori
viral
infect
defensin
famili
endogen
cysteinerich
peptid
typic
contain
sixcystein
motif
link
three
intramolecular
disulfid
bond
posit
defensin
secret
epitheli
cell
mucou
membran
respiratori
digest
urinari
reproduct
tract
provid
firstlin
defens
variou
infecti
pathogen
includ
number
envelop
virus
antivir
activ
defensin
thought
mediat
either
indirect
interact
direct
interact
viral
glycoprotein
andor
envelop
exampl
defensin
could
indirectli
interact
viral
receptor
andor
glycoprotein
target
cell
inhibit
virusreceptor
bind
viruscel
membran
fusion
downregul
cellsign
pathway
requir
viral
replic
defensin
might
also
directli
interact
viral
glycoprotein
andor
disrupt
viral
envelop
inhibit
viral
entri
target
cell
recent
also
found
mous
strong
vitro
vivo
antivir
effect
influenza
virus
sarscov
unpublish
data
despit
remark
antivir
activ
differ
envelop
virus
develop
defensin
therapeut
hinder
sever
factor
suboptim
efficaci
side
effect
lack
costeffect
mean
largescal
product
short
peptid
deriv
human
recent
shown
contain
potent
antibacteri
effect
lower
toxic
host
cell
human
therefor
design
synthes
short
peptid
deriv
investig
studi
identifi
short
peptid
deriv
could
inhibit
broad
short
peptid
exhibit
highest
antivir
activ
among
peptid
eleven
peptid
design
synthes
tabl
antivir
activ
influenza
viru
evalu
mdck
cell
among
short
peptid
show
strongest
antivir
activ
fig
interestingli
dosedepend
antivir
effect
stronger
synthet
recombin
particular
inhibitori
concentr
ic
gml
lower
gml
gml
fig
furthermor
toxic
concentr
tc
gml
respect
fig
select
index
higher
notabl
liquid
form
powder
form
demonstr
stabl
shelf
live
exhibit
similar
antivir
activ
store
year
supplementari
fig
taken
togeth
among
peptid
deriv
exhibit
highest
antivir
activ
select
index
thu
select
studi
protect
mice
lethal
challeng
viru
evalu
prophylact
therapeut
effect
lethal
mous
model
influenza
fig
mice
intranas
inocul
gmous
challeng
lethal
dose
viru
dose
gmous
appli
anim
experi
shown
protect
mice
lethal
challeng
viru
surviv
rate
mice
significantli
higher
mice
p
untreat
mice
p
notabl
pretreat
zanamivir
achiev
similar
protect
effect
fig
parallel
mice
inocul
dose
gdoseday
zanamivir
six
hour
lethal
challeng
viru
fig
surviv
rate
mice
significantli
higher
untreat
control
mice
p
set
treatment
zanamivir
yield
similar
level
protect
comparison
p
infect
mice
suffer
bodi
weight
lost
regardless
treatment
type
howev
surviv
mice
began
regain
bodi
weight
day
postinfect
fig
viral
rna
copi
viral
titer
lung
tissu
infect
mice
detect
realtim
rtpcr
fig
plaqu
assay
fig
respect
viral
load
lung
tissu
mice
significantli
lower
untreat
mice
p
histopatholog
examin
reveal
alveolar
damag
interstiti
inflammatori
infiltr
untreat
mice
mice
pretreat
treat
substanti
sever
mice
pretreat
treat
fig
stabil
vivo
evalu
biodistribut
mous
lung
antivir
activ
differ
timepoint
administr
shown
supplementari
fig
could
detect
surfac
mous
bronchial
tub
min
h
h
administr
signal
decreas
almost
undetect
level
h
administr
vivo
protect
experi
administr
mice
h
h
h
challeng
protect
mice
lethal
challeng
viru
respect
supplementari
fig
result
indic
could
maintain
half
antivir
activ
hour
antivir
activ
hour
administr
vivo
toxic
also
assess
mice
mous
inocul
mgkg
intraperiton
ip
inject
mgkg
per
day
day
shown
supplementari
fig
less
bodi
weight
loss
observ
first
day
bodi
weight
began
recov
treatment
stop
day
obviou
reduct
food
consumpt
sick
observ
period
collect
data
demonstr
exhibit
prophylact
therapeut
effect
lethal
challeng
viru
mice
accompani
low
toxic
vivo
tigat
antivir
mechan
first
seek
determin
whether
inhibit
viru
entri
replic
releas
supplement
cultur
medium
hour
mdck
cell
infect
viru
moi
viral
rna
copi
insid
cell
fig
cultur
supernat
fig
harvest
indic
hour
postinfect
compar
untreat
control
p
result
suggest
inhibit
viral
replic
releas
viru
pretreat
ad
cell
moi
viral
load
insid
cell
fig
cultur
supernat
significantli
reduc
supplementari
fig
b
contrast
viral
load
insid
cell
fig
supernat
supplementari
fig
similar
untreat
control
cell
pretreat
follow
infect
result
indic
inhibit
viru
infect
interact
directli
viru
demonstr
could
bind
surfac
glycoprotein
ha
influenza
viru
fig
f
merscov
supplementari
fig
togeth
result
indic
inhibit
viral
infect
bind
viral
surfac
glycoprotein
block
viral
rna
releas
late
endosom
dissect
interf
influenza
viru
infect
ask
whether
virusreceptor
bind
endocytosi
viral
rna
releas
affect
viru
carri
green
fluoresc
label
pretreat
incub
cell
efficaci
differ
concentr
detect
cultur
mdck
cell
inhibitori
activ
directli
determin
plaqu
assay
infect
ratio
calcul
plaqu
number
treat
samplesplaqu
number
untreat
sampl
ic
indic
dot
line
indic
mean
ic
gml
gml
gml
respect
c
cytotox
determin
mtt
assay
tc
indic
dot
line
data
present
mean
sd
three
independ
experi
hour
found
viru
bound
cellular
membran
similar
manner
compar
untreat
viru
fig
left
viru
enter
cell
endocytosi
viru
incub
hour
fig
middl
furthermor
transport
viru
endosom
cell
peripheri
proxim
nucleu
affect
viru
pretreat
fig
right
coloc
viru
confirm
bind
viru
intern
cell
subsequ
transport
perinuclear
region
togeth
viru
fig
hand
level
viral
rna
infect
cell
remain
essenti
unchang
first
hour
postinfect
regardless
treatment
fig
suggest
inhibit
viral
bind
entri
viral
rna
level
cell
infect
untreat
viru
increas
hour
postinfect
indic
initi
nascent
viral
rna
replic
contrast
viral
rna
level
cell
infect
viru
increas
hour
postinfect
significantli
lower
untreat
viru
control
p
fig
result
implic
perturb
viral
uncoat
viral
rna
releas
late
endosom
subsequ
replic
uncoat
subsequ
genom
releas
bear
mind
basic
amino
acidrich
composit
examin
whether
could
block
viral
rna
releas
counteract
endosom
acidif
shown
fig
show
similar
antivir
effect
comparison
ammonium
chlorid
nh
cl
bafilomycin
welldefin
inhibitor
endosom
acidif
contrast
zanamivir
inhibit
viral
releas
show
similar
antivir
kinet
comparison
endosom
acidif
inhibitor
therefor
nh
cl
bafilomycin
might
share
similar
antivir
mechan
inhibit
ph
decreas
endosom
confirm
hypothesi
detect
ph
chang
endosom
use
phsensit
dye
intens
mirror
acid
cellular
milieu
red
signal
cell
infect
untreat
viru
vc
indic
acidif
process
endosom
fig
contrast
control
cell
infect
viru
pretreat
nh
cl
bafilomycin
littl
red
signal
observ
indic
acidif
abolish
endosom
verifi
design
analog
name
contain
three
addit
acid
amino
acid
cterminu
tabl
act
perturb
ph
lower
addit
acid
residu
expect
reliev
perturb
abrog
consequ
antivir
effect
inde
confoc
microscop
imag
indic
ph
lower
endosom
unaffect
fig
line
imag
result
lost
antivir
activ
ic
gml
addit
polykaryon
assay
show
directli
inhibit
hacel
membran
fusion
supplementari
fig
henc
deliv
endosom
virusbound
prevent
ph
decreas
result
inhibit
viral
rna
releas
subsequ
replic
next
evalu
whether
could
inhibit
subtyp
influenza
viru
respiratori
virus
sarscov
merscov
depend
endosom
acidif
viral
infect
data
demonstr
exhibit
strong
antivir
effect
subtyp
influenza
viru
includ
ic
rang
gml
fig
ic
sarscov
merscov
gml
notabl
concentr
higher
gml
could
inhibit
sarscov
merscov
infect
fig
result
indic
broadspectrum
antivir
activ
vitro
multipl
respiratori
virus
evalu
protect
effect
infect
sar
virus
mice
shown
fig
one
dose
gmous
prophylaxi
dose
gmous
therapi
could
protect
mice
lethal
challeng
viru
respect
protect
rate
significantli
higher
untreat
mice
p
compar
mice
treat
prophylact
therapeut
zanamivir
zana
p
one
dose
prophylaxi
dose
therapi
protect
mice
lethal
challeng
viru
respect
treatment
group
provid
significantli
protect
control
group
p
surviv
rate
mice
treat
prophylact
therapeut
zanamivir
respect
show
signific
differ
compar
mice
p
fig
bodi
weight
treat
untreat
mice
began
decreas
day
postchalleng
gradual
recov
day
postinfect
surviv
mice
fig
f
sinc
establish
anim
model
lethal
infect
merscov
sarscov
compar
viral
load
mous
lung
day
postinfect
mous
model
nonleth
sarscov
infect
shown
fig
h
one
dose
prophylaxi
dose
therapi
significantli
inhibit
viru
infect
mous
lung
compar
untreat
mous
lung
studi
found
short
peptid
exhibit
highest
antivir
activ
influenza
viru
among
panel
peptid
fig
time
show
lowest
cytotox
vitro
result
improv
select
index
parent
particularli
noteworthi
display
potent
prophylact
therapeut
effect
mice
fig
product
recombin
bd
hamper
high
cost
low
recoveri
rate
supplementari
fig
contrast
chemic
synthes
high
yield
low
cost
synthet
highli
solubl
stabl
water
well
reason
stabl
vivo
make
ideal
lead
compound
develop
novel
antivir
drug
report
antivir
activ
bd
might
mediat
either
indirect
interact
direct
interact
viral
glycoprotein
andor
envelop
demonstr
bind
viral
glycoprotein
fig
f
supplementari
fig
target
cell
fig
infect
influenza
viru
involv
multipl
step
includ
virusreceptor
bind
endocytosi
transport
earli
endosom
late
endosom
acidif
result
virusendosom
membran
fusion
subsequ
viral
disassembl
uncoat
viral
rna
releas
trigger
viral
rna
replic
demonstr
might
mitig
viral
rna
releas
late
endosom
inhibit
viral
rna
replic
fig
sinc
ph
lower
late
endosom
critic
virusendosom
membran
fusion
inhibitor
endosom
acidif
effici
inhibit
membran
fusion
suppress
ph
decreas
endosom
inde
capabl
inhibit
ph
decreas
endosom
similar
fashion
compar
two
wellcharacter
inhibitor
endosom
acidif
nh
cl
bafilomycin
fig
thu
data
suggest
inhibit
viral
rna
releas
suppress
ph
decreas
endosom
antivir
function
mediat
inhibit
endosom
acidif
might
independ
block
ion
channel
sinc
could
effici
inhibit
infect
three
amantadineresist
strain
influenza
viru
ahong
fig
importantli
substanti
number
pathogen
virus
includ
influenza
viru
coronaviru
virusendosom
membran
fusion
prerequisit
viral
disassembl
viral
genom
releas
host
cell
initi
product
viral
replic
membran
fusion
mediat
viral
envelop
glycoprotein
requir
acid
environ
endosom
line
antivir
mechan
illustr
studi
could
inhibit
infect
subtyp
influenza
viru
includ
well
two
coronavirus
sarscov
merscov
fig
result
also
demonstr
could
bind
merscov
supplementari
fig
suggest
antivir
mechan
sarscov
merscov
potenti
similar
influenza
viru
reason
might
capabl
inhibit
infect
addit
pathogen
virus
enter
target
cell
via
endocytosi
long
could
effici
bind
viral
particl
summari
demonstr
short
peptid
deriv
broadspectrum
antivir
activ
differ
subtyp
influenza
viru
includ
well
two
coronavirus
sarscov
merscov
antivir
effect
mediat
follow
mechan
effici
bind
viral
particl
via
viral
glycoprotein
rich
basic
amino
acid
prevent
acidif
endosom
inhibit
viral
rna
releas
influenza
viru
coronaviru
caus
sever
fatal
pandem
outbreak
past
centuri
although
number
antiinfluenza
drug
develop
drugresist
viru
strain
emerg
quickli
antivir
drug
put
clinic
use
addit
thu
far
effect
antivir
drug
avail
patient
infect
sarscov
merscov
regard
antivir
peptid
repres
new
promis
prophylact
therapeut
agent
broadspectrum
antivir
activ
overal
base
mechan
illustr
studi
new
antivir
peptid
broadspectrum
antivir
activ
may
develop
provid
new
drug
prophylaxi
therapi
viral
infect
clone
express
purif
codon
optim
e
colipref
codon
base
optim
supplementari
fig
fragment
gener
pcrbase
gene
synthesi
use
oligo
supplementari
fig
codonoptim
gene
clone
vector
subclon
kpni
xhoi
site
result
plasmid
transform
express
fusion
protein
releas
e
coli
simpl
osmot
shock
procedur
purifi
aktafplc
ge
healthcar
littl
chalfont
buckinghamshir
unit
kingdom
use
trap
ff
column
ge
healthcar
supplementari
fig
digest
enterokinas
releas
recombin
recov
cationexchang
chromatographi
use
sp
sepharos
ff
ge
healthcar
purifi
desalt
use
column
ge
healthcar
mm
hepe
buffer
ph
supplementari
fig
peptid
design
evalu
antivir
effect
fulllength
short
peptid
deriv
design
shown
tabl
synthes
chinapeptid
shanghai
puriti
peptid
puriti
mass
peptid
verifi
hplc
mass
spectrometri
antivir
effect
short
peptid
initi
evalu
lowsalt
medium
ie
mm
phosphat
buffer
pb
contain
mm
na
hpo
mm
kh
po
ph
highsalt
minimum
essenti
medium
mem
peptid
gml
premix
viru
pb
mem
incub
room
temperatur
hour
mdck
cell
infect
peptidepretr
untreat
viru
zanamivir
gml
maintain
cultur
medium
posit
control
antivir
activ
peptid
measur
use
plaqu
reduct
assay
describ
previous
infect
ratio
calcul
plaqu
number
viru
pretreat
peptid
divid
plaqu
number
viru
pretreat
pb
mem
cytotox
ic
assay
cytotox
peptid
determin
detect
toxic
concentr
tc
use
tetrazoliumbas
colorimetr
mtt
assay
describ
previous
briefli
exchang
solut
buffer
peptid
distil
water
concentr
vacuum
dryer
toxic
assay
mdck
cell
seed
cell
cultur
plate
initi
densiti
cell
well
l
mem
supplement
fb
incub
overnight
cell
wash
twice
pb
ad
lwell
mem
variou
concentr
peptid
experi
done
triplic
incub
hour
mtt
solut
mgml
lwell
ad
plate
plate
incub
hour
l
sd
hcl
ad
well
incub
overnight
plate
read
od
od
use
victor
tm
multilabel
reader
perkinelm
cell
cultur
well
without
peptid
use
experi
control
medium
serv
blank
control
ic
peptid
differ
subtyp
influenza
viru
ie
coronavirus
sarscov
merscov
calcul
infect
ratio
viru
treat
variou
concentr
peptid
scientif
report
doi
evalu
antivir
effect
vivo
balbc
femal
mice
week
old
kept
biosafeti
level
laboratori
given
access
standard
pellet
feed
water
ad
libitum
experi
carri
accord
approv
guidelin
biosafeti
level
anim
facil
approv
committe
use
live
anim
teach
research
univers
hong
kong
mous
adapt
virus
use
lethal
challeng
mice
evalu
prophylact
effect
mice
inocul
pb
zanamivir
challeng
ld
viru
min
later
evalu
therapeut
effect
mice
challeng
ld
viru
inocul
zanamivir
six
hour
viral
inocul
two
dose
given
mice
four
dose
given
mice
interv
surviv
gener
condit
monitor
day
death
virolog
patholog
test
mice
group
sacrif
day
challeng
evalu
vivo
prophylact
effect
sarscov
infect
ninemonth
old
mice
inocul
gmous
challeng
tcid
sarscov
evalu
therapeut
effect
mice
challeng
tcid
sarscov
inocul
hour
postinfect
four
dose
given
mice
follow
two
day
lung
tissu
collect
day
postinfect
virolog
assay
inocul
perform
use
microspray
aerosol
penncenturi
usa
least
nine
mice
group
analyz
anim
experi
histopatholog
stain
lung
tissu
collect
challeng
mice
immedi
fix
buffer
formalin
appli
dehydr
embed
paraffin
wax
section
thick
mount
slide
histopatholog
chang
examin
hematoxylin
eosin
h
e
stain
light
microscop
describ
previous
viral
rna
extract
realtim
rtpcr
viral
load
detect
realtim
rtpcr
describ
previous
viral
rna
extract
cultur
supernat
use
rneasi
mini
kit
qiagen
viral
rna
cell
lysi
mous
lung
tissu
extract
use
qiaamp
viral
rna
mini
kit
qiagen
accord
manufactur
protocol
revers
transcript
perform
use
rsii
kit
invitrogen
accord
manufactur
instruct
realtim
pcr
perform
use
abi
sybr
green
mastermix
system
clone
ha
gene
viru
serv
posit
control
standard
realtim
pcr
experi
perform
triplic
fluoresc
imag
viru
label
green
fluoresc
lipophil
dye
dio
invitrogen
detect
dilut
primari
antibodi
max
biotechnolog
co
ltd
china
dilut
secondari
antibodi
goat
antirabbit
alexa
invitrogen
cell
membran
stain
dye
alexa
invitrogen
label
viru
premix
hour
incub
mdck
cell
infect
cell
fix
formalin
differ
time
point
infect
cell
permeabl
triton
react
correspond
antibodi
imag
taken
confoc
microscop
carl
zeiss
lsm
polykaryon
assay
cell
seed
plate
cell
per
well
hour
cultur
cell
transfect
plasmid
gwell
use
lipofectamin
life
technolog
follow
manufactur
instruct
hour
transfect
transfect
medium
replac
plain
dmem
cell
treat
trypsin
gml
min
rins
cell
plain
dmem
cell
preincub
dmso
dmem
min
polykaryon
format
induc
expos
cell
low
ph
dmem
ph
contain
correspond
concentr
dmso
min
low
ph
medium
replac
dmem
contain
fb
cell
incub
h
final
cell
fix
buffer
formalin
stain
giemsa
sigma
imag
taken
microscop
magnif
accord
instruct
provid
manufactur
phsensit
dye
phrodo
red
dextran
invitrogen
viru
prelabel
dio
incub
peptid
nh
cl
bafilomycin
pb
untreat
room
temperatur
min
follow
incub
min
mdck
cell
inocul
moi
untreat
viru
incub
hour
gml
phsensit
dye
ad
cell
incub
continu
min
take
imag
cell
cultur
min
cell
wash
two
time
pb
final
fresh
media
ad
cell
imag
taken
immedi
confoc
microscop
perkin
elmer
spin
confoc
microscop
western
blot
assay
viral
protein
bound
identifi
western
blot
assay
describ
previous
briefli
viral
protein
sampl
separ
sdspage
transfer
polyvinyliden
difluorid
pvdf
membran
transfer
membran
incub
gml
room
temperatur
h
follow
incub
rabbit
h
detect
bind
detect
ha
na
membran
incub
immun
technolog
crop
rabbitantina
immun
technolog
crop
sino
biolog
inc
sino
biolog
inc
room
temperatur
h
goat
antirabbit
igghrp
invitrogen
use
secondari
antibodi
detect
bind
room
temperatur
h
membran
probe
indic
antibodi
peptid
immunoreact
band
visual
enhanc
chemiluminesc
